Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells

Journal of Endocrinology

Volumn 183, Issue 3, 2004, Pages 445-454

  Schutt M ^b   Zhou, J ^b   Meier, M ^b   Klein, Harald ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; GLUCOSE; INDINAVIR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; NELFINAVIR; PROTEIN KINASE B; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; THREONINE;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INCUBATION TIME; INSULIN RELEASE; INSULIN RESISTANCE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPERNATANT;

CARBAMATES; CELL LINE; GLUCOSE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISLETS OF LANGERHANS; NELFINAVIR; PHOSPHOPROTEINS; PHOSPHORYLATION; RITONAVIR; SAQUINAVIR; SIGNAL TRANSDUCTION; STIMULATION, CHEMICAL; SULFONAMIDES; TIME FACTORS;

EID: 11244351796     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.05620     Document Type: Article

References (38)

1. Acosta EP & King JR 2003 Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clinical Infectious Diseases 36 373-377.
2. Ben-Romano R, Rudich A, Torok D, Vanounou S, Riesenberg K, Schlaeffer F, Klip A & Bashan N 2003 Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 17 23-32.
3. Ben-Romano R, Rudich A, Tirosh A, Potashnik R, Sasaoka T, Riesenberg K, Schlaeffer F & Bashan N 2004 Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-ξ. Diabetologia 47 1107-1117.
4. Cammalleri C & Germinario RJ 2003 The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. Journal of Lipid Research 44 103-108.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA 1999 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353 2093-2099.
6. Cheng M, Chen S, Schow SR, Manchem VP, Spevak WR, Cristobal CP, Shi S, Macsata RW, Lum RT, Goldfine ID & Keck JG 2004 In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator. Journal of Cellular Biochemistry 92 1234-1245.
7. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, Williams V, Johnson D & Buchanan TA 2002 Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clinical Infectious Diseases 13 475-481.
8. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE & Janssen RS 2002 Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 1747-1748.
9. Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, Finzi G, Usellini L, Placidi C, Capella C et al. 2003 Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta-cell line and human islets of Langerhans. FASEB Journal 17 1340-1342.
10. Hruz PW, Murata H, Qiu H & Mueckler M 2002 Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51 937-942.
11. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S & Jones JL 2000 Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 30 (suppl 1) 5-14.
12. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF & Accili D 2000 Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. Journal of Clinical Investigation 105 199-205.
13. Koster JC, Remedi MS, Qiu H, Nichols CG & Hruz PW 2003 HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52 1695-1700.
14. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H et al. 2000 Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49 1880-1889.
15. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D & Kahn CR 1999a Altered function of insulin receptor substrate-1-deficient mouse islets and cultured β-cell lines. Journal of Clinical Investigation 104 69-75.
16. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA & Kahn CR 1999b Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 329-339.
17. Leibiger IB, Leibiger B & Berggren PO 2002 Insulin feedback action on pancreatic β-cell function. FEBS Letters 532 1-6.
18. Lenhard JM, Croom DK, Weiel JE & Winegar DA 2000a HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology 20 2625-2629.
19. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA & Weiel JE 2000b HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Research 47 121-129.
20. Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, Del Guerra S, Patane G, Piro S, Anello M et al. 2002 Insulin secretory function is impaired in isolated human islets carrying the Gly(972)→Arg IRS-1 polymorphism. Diabetes 51 1419-1424.
21. Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H & Klein HH (2002) Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 51 2691-2697.
22. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM et al. 1998 Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250 255-262.
23. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65 55-63.
24. Murata H, Hruz PW & Mueckler M 2000 The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 275 20251-20254.
25. Murata H, Hruz PW & Mueckler M 2002 Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16 859-863.
26. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M & Grunfeld C 2001 Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15 11-18.
27. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M & Grunfeld C 2002 Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16 1-8.
28. Ohsugi M, Cras-Meneur C, Zhou Y, Warren W, Bernal-Mizrachi E & Permutt MA 2004 Glucose and insulin treatment of insulinoma cells results in transcriptional regulation of a common set of genes. Diabetes 53 1496-1508.
29. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R et al. 1999 Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 17 700-705.
30. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, Greenberg AS, Schlaeffer F & Bashan N 2001 The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 50 1425-1431.
31. Schütt M, Meier M, Meyer M, Klein J, Aries SP & Klein HH 2000 The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia 43 1145-1148.
32. Schütt M, Meier M, Jost MM & Klein HH 2003 The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells. Experimental and Clinical Endocrinology & Diabetes 111 16-20.
33. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R & Goebel ED 1998 Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12 167-173.
34. White MF 2002 IRS proteins and the common path to diabetes. American Journal of Physiology - Endocrinology and Metabolism 283 413-422.
35. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL & Gerich JE 2003 Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52 918-925.
36. Wu YB, Hagen KL, Shen ML & Ou DW 2003 Evidence of increased DNA content of murine thymocytes caused by cocaine. Immunopharmacology and Immunotoxicology 25 53-64.
37. Yang C, Chang TJ, Chang JC, Liu MW, Tai TY, Hsu WH & Chuang LM 2001 Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes 50 2598-2602.
38. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE & Powderly WG 1999 Insulin resistance in HIV protease inhibitor-associated diabetes. Journal of Acquired Immune Deficiency Syndromes 21 209-216.